Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 525

1.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC.

J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.

PMID:
18235122
[PubMed - indexed for MEDLINE]
2.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.

J Clin Oncol. 2008 Feb 1;26(4):620-5. doi: 10.1200/JCO.2007.13.4403.

PMID:
18235121
[PubMed - indexed for MEDLINE]
3.

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA.

J Clin Oncol. 2008 Nov 20;26(33):5360-7. doi: 10.1200/JCO.2008.17.4284. Epub 2008 Oct 27.

PMID:
18955451
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.

Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23.

PMID:
19307738
[PubMed - indexed for MEDLINE]
5.

Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Park I, Ryu MH, Sym SJ, Lee SS, Jang G, Kim TW, Chang HM, Lee JL, Lee H, Kang YK.

Jpn J Clin Oncol. 2009 Feb;39(2):105-10. doi: 10.1093/jjco/hyn134. Epub 2008 Dec 3.

PMID:
19052040
[PubMed - indexed for MEDLINE]
Free Article
6.

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Kerbrat P, Fayette J, Chabaud S, Berthaud P, Perol D.

J Clin Oncol. 2007 Mar 20;25(9):1107-13.

PMID:
17369574
[PubMed - indexed for MEDLINE]
7.

Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.

Al-Batran SE, Hartmann JT, Heidel F, Stoehlmacher J, Wardelmann E, Dechow C, Düx M, Izbicki JR, Kraus T, Fischer T, Jäger E.

Gastric Cancer. 2007;10(3):145-52. Epub 2007 Sep 26.

PMID:
17922091
[PubMed - indexed for MEDLINE]
8.

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.

Health Technol Assess. 2005 Jul;9(25):1-142. Review.

PMID:
15985189
[PubMed - indexed for MEDLINE]
Free Article
9.

Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Croom KF, Perry CM.

Drugs. 2003;63(5):513-22; discussion 523-4. Review.

PMID:
12600228
[PubMed - indexed for MEDLINE]
10.

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.

Eur J Cancer. 2010 May;46(8):1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.

PMID:
20211560
[PubMed - indexed for MEDLINE]
11.

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.

Maurel J, Martins AS, Poveda A, López-Guerrero JA, Cubedo R, Casado A, Martínez-Trufero J, Ramón Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E.

Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111.

PMID:
20564079
[PubMed - indexed for MEDLINE]
Free Article
12.

[Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].

Shen L, Jin ML.

Zhonghua Zhong Liu Za Zhi. 2004 Nov;26(11):697-9. Chinese.

PMID:
15777512
[PubMed - indexed for MEDLINE]
13.

[Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].

Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR.

Zhonghua Yi Xue Za Zhi. 2006 Nov 21;86(43):3064-7. Chinese.

PMID:
17288838
[PubMed - indexed for MEDLINE]
14.

Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, Kim KH, Yook JH, Kim BS, Kang YK.

J Surg Oncol. 2008 Jul 1;98(1):27-33. doi: 10.1002/jso.21065.

PMID:
18452195
[PubMed - indexed for MEDLINE]
15.

Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.

Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK.

J Manag Care Pharm. 2010 Sep;16(7):482-91.

PMID:
20726677
[PubMed - indexed for MEDLINE]
Free Article
16.

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).

Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W.

J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. Epub 2007 Apr 26.

PMID:
17458563
[PubMed - indexed for MEDLINE]
17.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R.

Clin Cancer Res. 2002 Oct;8(10):3034-8.

PMID:
12374669
[PubMed - indexed for MEDLINE]
Free Article
18.

Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.

Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.

Anticancer Drugs. 2008 Jul;19(6):607-12. doi: 10.1097/CAD.0b013e32830138f9.

PMID:
18525320
[PubMed - indexed for MEDLINE]
19.

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.

Patel S, Zalcberg JR.

Eur J Cancer. 2008 Mar;44(4):501-9. doi: 10.1016/j.ejca.2007.11.021. Epub 2008 Jan 29. Review.

PMID:
18234488
[PubMed - indexed for MEDLINE]
20.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Cohen MH, Farrell A, Justice R, Pazdur R.

Oncologist. 2009 Feb;14(2):174-80. doi: 10.1634/theoncologist.2008-0255. Epub 2009 Feb 4.

PMID:
19193781
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk